{"id":19610,"date":"2025-03-10T19:51:02","date_gmt":"2025-03-10T19:51:02","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/tci-biotech-announces-strong-2024-financial-performance-sets-sights-on-global-growth-in-2025\/"},"modified":"2025-03-10T19:51:02","modified_gmt":"2025-03-10T19:51:02","slug":"tci-biotech-announces-strong-2024-financial-performance-sets-sights-on-global-growth-in-2025","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=19610","title":{"rendered":"TCI Biotech Announces Strong 2024 Financial Performance, Sets Sights on Global Growth in 2025"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 10, 2025<\/span><\/span> \/PRNewswire\/ &#8212; TCI Biotech (TCI Co., Ltd.) (TWSE: 8436), a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year ending <span class=\"xn-chron\">December 31, 2024<\/span>. The company reported steady revenue performance, strong profitability, and continued investment in innovation to drive future growth.<\/p>\n<p><b>Executive Commentary<\/b><\/p>\n<p>&#8220;Our 2024 financial performance underscores TCI Biotech&#8217;s resilience and ability to navigate market fluctuations while maintaining strong profitability,&#8221; said <span class=\"xn-person\">Vincent Lin<\/span>, CEO of TCI Biotech. &#8220;We remain committed to expanding smart manufacturing, fostering strategic partnerships, and driving cutting-edge research. By strengthening our financial position, we aim to deliver sustainable growth and long-term value for our stakeholders.&#8221;<\/p>\n<p><b>Financial Highlights<\/b><\/p>\n<ul type=\"disc\">\n<li>Revenue: <span class=\"xn-money\">NT$7.24 billion<\/span> in 2024<\/li>\n<li>Gross Profit: <span class=\"xn-money\">NT$3.18 billion<\/span>, representing a gross margin of 44%<\/li>\n<li>Operating Profit: <span class=\"xn-money\">NT$1.03 billion<\/span>, maintaining a stable 14% operating margin<\/li>\n<li>Net Profit: <span class=\"xn-money\">NT$974 million<\/span>, with earnings per share (EPS) of <span class=\"xn-money\">NT$7.60<\/span><\/li>\n<li>Dividend: <span class=\"xn-money\">NT$10<\/span> per share, reflecting solid financial performance<\/li>\n<li>Cash and Cash Equivalents: <span class=\"xn-money\">NT$4.77 billion<\/span>, ensuring strong liquidity<\/li>\n<\/ul>\n<p><b>Key Business Developments<\/b><\/p>\n<ul type=\"disc\">\n<li>Expansion in International Markets: Sales growth in key regions, including <span class=\"xn-location\">North America<\/span>, <span class=\"xn-location\">Europe<\/span>, <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">Asia<\/span>, reinforcing TCI Biotech&#8217;s global footprint.<\/li>\n<li>Innovation &amp; R&amp;D: Advances in liquid supplements and skincare, aligned with market trends. The newly established TCI Medical Consultation Panel enhances research and ensures scientific rigor.<\/li>\n<li>Operational Efficiency: Strategic cost management and AI-enhanced production processes have contributed to maintaining profitability despite industry challenges.<\/li>\n<li>Sustainable Growth Strategies: Continued commitment to ESG (Environmental, Social and Governance) initiatives to enhance corporate responsibility and long-term value creation.<\/li>\n<\/ul>\n<p><b>Outlook for 2025<\/b><\/p>\n<p>TCI Biotech is optimistic about its growth trajectory for 2025, focusing on balanced regional expansion, optimized production capacity, and strategic partnerships with global enterprises. With a commitment to quality, innovation, and customer-centric solutions, the company anticipates sustained momentum in revenue and profitability, reinforcing its position as a leader in biotechnology and smart manufacturing.<\/p>\n<p>For more information, please visit <u><a href=\"https:\/\/www.tci-bio.com\/\" target=\"_blank\" rel=\"nofollow\">www.tci-bio.com<\/a><\/u>.<\/p>\n<p><b>About TCI Biotech<\/b><\/p>\n<p>TCI Biotech (TCI Co., Ltd.) is a global leader in CDMO+ services, specializing in the research, development, and manufacturing of health foods and cosmetics. Committed to innovation and scientific excellence, TCI delivers high-quality, clinically backed products that empower customers worldwide.<\/p>\n<p>Disclaimer: This press release contains forward-looking statements based on current expectations and assumptions, which involve risks and uncertainties. Actual results may differ due to market conditions, regulatory changes, or other unforeseen factors. <span>TCI<\/span>\u00a0Biotech assumes no obligation to update forward-looking statements. Investors are advised to review the full financial report and consult professional advisors before making any investment decisions.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">TAIPEI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 10, 2025<\/span><\/span> \/PRNewswire\/ &#8212; TCI Biotech (TCI Co., Ltd.) (TWSE: 8436), a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year ending <span class=\"xn-chron\">December 31, 2024<\/span>. The company reported steady revenue performance, strong profitability, and continued investment in innovation to drive future growth.<\/p>\n<p><b>Executive Commentary<\/b><\/p>\n<p>&#8220;Our 2024 financial performance underscores TCI Biotech&#8217;s resilience and ability to navigate market fluctuations while maintaining strong profitability,&#8221; said <span class=\"xn-person\">Vincent Lin<\/span>, CEO of TCI Biotech. &#8220;We remain committed to expanding smart manufacturing, fostering strategic partnerships, and driving cutting-edge research. By strengthening our financial position, we aim to deliver sustainable growth and long-term value for our stakeholders.&#8221;<\/p>\n<p><b>Financial Highlights<\/b><\/p>\n<ul type=\"disc\">\n<li>Revenue: <span class=\"xn-money\">NT$7.24 billion<\/span> in 2024<\/li>\n<li>Gross Profit: <span class=\"xn-money\">NT$3.18 billion<\/span>, representing a gross margin of 44%<\/li>\n<li>Operating Profit: <span class=\"xn-money\">NT$1.03 billion<\/span>, maintaining a stable 14% operating margin<\/li>\n<li>Net Profit: <span class=\"xn-money\">NT$974 million<\/span>, with earnings per share (EPS) of <span class=\"xn-money\">NT$7.60<\/span><\/li>\n<li>Dividend: <span class=\"xn-money\">NT$10<\/span> per share, reflecting solid financial performance<\/li>\n<li>Cash and Cash Equivalents: <span class=\"xn-money\">NT$4.77 billion<\/span>, ensuring strong liquidity<\/li>\n<\/ul>\n<p><b>Key Business Developments<\/b><\/p>\n<ul type=\"disc\">\n<li>Expansion in International Markets: Sales growth in key regions, including <span class=\"xn-location\">North America<\/span>, <span class=\"xn-location\">Europe<\/span>, <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">Asia<\/span>, reinforcing TCI Biotech&#8217;s global footprint.<\/li>\n<li>Innovation &amp; R&amp;D: Advances in liquid supplements and skincare, aligned with market trends. The newly established TCI Medical Consultation Panel enhances research and ensures scientific rigor.<\/li>\n<li>Operational Efficiency: Strategic cost management and AI-enhanced production processes have contributed to maintaining profitability despite industry challenges.<\/li>\n<li>Sustainable Growth Strategies: Continued commitment to ESG (Environmental, Social and Governance) initiatives to enhance corporate responsibility and long-term value creation.<\/li>\n<\/ul>\n<p><b>Outlook for 2025<\/b><\/p>\n<p>TCI Biotech is optimistic about its growth trajectory for 2025, focusing on balanced regional expansion, optimized production capacity, and strategic partnerships with global enterprises. With a commitment to quality, innovation, and customer-centric solutions, the company anticipates sustained momentum in revenue and profitability, reinforcing its position as a leader in biotechnology and smart manufacturing.<\/p>\n<p>For more information, please visit <u><a href=\"https:\/\/www.tci-bio.com\/\" target=\"_blank\" rel=\"nofollow\">www.tci-bio.com<\/a><\/u>.<\/p>\n<p><b>About TCI Biotech<\/b><\/p>\n<p>TCI Biotech (TCI Co., Ltd.) is a global leader in CDMO+ services, specializing in the research, development, and manufacturing of health foods and cosmetics. Committed to innovation and scientific excellence, TCI delivers high-quality, clinically backed products that empower customers worldwide.<\/p>\n<p>Disclaimer: This press release contains forward-looking statements based on current expectations and assumptions, which involve risks and uncertainties. Actual results may differ due to market conditions, regulatory changes, or other unforeseen factors. <span>TCI<\/span>\u00a0Biotech assumes no obligation to update forward-looking statements. Investors are advised to review the full financial report and consult professional advisors before making any investment decisions.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-19610","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/19610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19610"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/19610\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}